drugset / Trial / NCT04504331
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
Phase 1
Terminated
4 enrolled
Jennifer Lee Caswell-Jin
National Cancer Institute (NCI) · collabQED Therapeutics, a BridgeBio company · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of the study is identify the dose(s) of infigratinib to use in combination with tamoxifen to treat patients with a particular type of advanced breast cancer (hormone receptor-positive, HER2-negative, FGFR-altered breast cancer)
Timeline
- Start
- 2020-10-13
- Primary completion
- 2021-10-22
- Completion
- 2021-10-22
Outcome
Outcome not reported
Stopped: “Drug manufacturer decision to terminate development.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Infigratinib | Small molecule | 75 mg | Oral |
| Subject | Infigratinib | Small molecule | 100 mg | Oral |
| Subject | Infigratinib | Small molecule | 125 mg | Oral |
| Background | Iopamidol | Diagnostic / imaging agent | — | Intravenous |
| Background | Omnipaque 350 | Diagnostic / imaging agent | — | Intravenous |
| Background | Tamoxifen | Small molecule | 20 mg | Oral |